Berlin, Germany
March 19-21

The program will focus on the latest challenges and innovations with a special emphasis on combination therapy, immuno-monitoring, and biomarker development.

At this conference, we are in particular addressing preclinical and clinical scientists, clinical investigators, postdoctoral fellows involved in cancer research, regulatory scientists, healthcare professionals, and the pharmaceutical industry.

Boston, MA
March 20-22

CAR-T Congress USA gathers 100+ thought leaders from biotech, big pharma, academia and investment to address the challenges and opportunities of CAR-T therapies in both liquid and solid tumors.

Hear from 25+ industry leaders including Ziopharm, Merck KGaA, GSK, Dana Farber, Celgene and leading research institutions to discuss the potential of CARs in alternative cell types, mechanisms behind toxicity and tumor targeting, how to improve patient access, the development of an ‘off-the-shelf’ product and commercializing this new cell therapy.

As a reader of ACIR, you will also benefit from an exclusive 10% discount, simply quote ACIR10 on registering.

*Update: The ACIR team attended several talks at the conference. You can read our coverage here.

Boston, MA
May 8-9

The Cancer Microbiome Congress will bring together academics, physicians, senior pharma executives and biotechs to learn about the developments and network to improve treatments in future. The speakers presenting at the congress include David Cook from Seres Therapeutics, the first company to develop live microbial therapeutics and Vancheswaran "Deepak" Gopalakrishnan from MD Anderson who published the groundbreaking paper identifying how the gut microbiome influences responses to Anti-PD1-Therapy. See the agenda for the Congress here.

As a reader of ACIR, you will also benefit from an exclusive 10% discount, simply quote ACIR10 on registering.

Mainz, Germany
May 15-17

The CIMT Annual Meeting connects the global cancer immunotherapy community in the heart of Europe. As the largest meeting focused on cancer immunotherapy research and development in Europe, CIMT 2018 invites international participants for high-level scientific exchange, collaboration, and education focused on cancer immunotherapy.

Plenary sessions will range from pre-clinical research to clinical development on the topics of therapeutic vaccination, cellular therapy, improving immunity, tumor microenvironment, antibodies, regulatory research and immunoguiding. There will also be a poster exhibit and selected poster short talk sessions, as well as industry symposia and industry exhibits.

London, UK
May 24-25

The 3rd Annual Advances in Immuno-Oncology Congress features over 50 presentations in a revamped conference programme that ensures you will benefit from the latest case studies and high-level scientific debate.

Discussion ranges across a variety of therapeutic strategies, from the discovery of combination therapies to vaccines to checkpoint inhibitors. Further talks look at genomic approaches to cancer immunotherapy and the impact of growing microbiome research on immuno-oncology.

Key Speakers include Chief Executives and Directors from AstraZeneca, Merck, GlaxoSmithKline, Glycostem and many more.

To register using ACIR 20% discount contact and quote IMMUNO20